Why the study?
Rates of VTE recurrence and bleeding remain high in patients with cancer receiving anticoagulants like LMWH after an initial VTE event, motivating an assessment of associated characteristics and secondary management.
In patients with cancer-associated thrombosis treated with LMWH, over 10% experience VTE recurrence or bleeding, highlighting a high residual risk that requires further prospective evaluation of anticoagulation strategies.
No takes yet. Share an insight, caveat, or question.
Identified characteristics may aid risk stratification for cancer VTE on LMWH; hypothesis-generating and requires prospective validation before guiding practice.
Mahé et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: